icon
icon
icon
icon
Upgrade
icon

Seattle Children's Therapeutics Receives G-Rex® Grant: A Boon for Pediatric Cell and Gene Therapies

AInvestWednesday, Jan 8, 2025 7:13 am ET
1min read



Seattle Children's Therapeutics, a pioneering nonprofit organization dedicated to developing next-generation cell and gene therapies for pediatric patients, has received a significant boost with the award of a G-Rex® Grant. This grant, valued at $250,000, is part of a $20 million initiative by ScaleReady, Wilson Wolf Manufacturing, Bio-Techne, and CellReady to advance the state of cell and gene-modified cell therapy (CGT) development and manufacturing.

The G-Rex® platform, developed by Wilson Wolf Manufacturing, is a scalable and cost-effective solution for manufacturing cell and gene therapies. It enables the production of large quantities of therapeutic cells in a controlled and efficient manner, making it an ideal platform for pediatric therapies, where smaller doses are often required. The platform's closed-system bioreactors also reduce the risk of contamination and improve overall efficiency, leading to faster production times and lower costs.

Seattle Children's Therapeutics plans to use the G-Rex® Grant funding to support the manufacturing process optimizations for TCB008, a novel CAR T-cell therapy for the treatment of solid tumors. The project aims to increase yields and reduce costs, making TCB008 more affordable for patients. The G-Rex® platform optimizations developed using the awarded grant will be implemented in the latter half of 2025, potentially accelerating the commercialization of TCB008.

The G-Rex® Grant will also provide Seattle Children's Therapeutics with access to exclusive support from ScaleReady's growing consortium of G-Rex® Grant Partners. This includes best-in-class tools and technologies, as well as unparalleled knowledge and expertise in cGMP manufacturing, quality, regulatory affairs, business operations, and more. This support will help Seattle Children's Therapeutics expedite process development and IND-enabling studies, as well as support clinical manufacturing runs of their autologous TCR-T cell therapy.



The G-Rex® Grant is a testament to the potential of Seattle Children's Therapeutics and its mission to create a new model of drug development that meets the unique needs of the pediatric population. By leveraging the G-Rex® platform and the expertise of its partners, Seattle Children's Therapeutics is well-positioned to bring new therapies to patients more quickly and efficiently, improving the lives of children with cancer and other diseases.

In conclusion, the G-Rex® Grant awarded to Seattle Children's Therapeutics is a significant milestone in the organization's quest to develop affordable and accessible cell and gene therapies for pediatric patients. The G-Rex® platform's scalability, cost-effectiveness, and efficiency, combined with the expertise of its partners, will enable Seattle Children's Therapeutics to accelerate the development and commercialization of novel therapies, ultimately benefiting children in need.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.